US 11,884,645 B2 · Sulfonyl acetamides as NLRP3 inhibitors

Abstract

The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha′-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

Claims20

Dependent claims

A compound of formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein:
Q is selected from 0 or S;
R1 is a 5-membered heteroaryl group, wherein the 5-membered ring structure consists of one or more carbon atoms, one or more nitrogen atoms and optionally one or more oxygen atoms, wherein R1 is substituted with R6 and R1 may optionally be further substituted;
R2 is a cyclic group substituted at the α and α′ positions, wherein R2 may optionally be further substituted;
R3 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2;
R4 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2;
or
R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated cyclic group, wherein the cyclic group may optionally be substituted;
R5 is independently an optionally substituted C1-C4 alkyl group;
and
R6 is any group comprising a nitrogen atom;
provided the compound is not

9 more elements

Dependencies are inferred from the claim text.

Sulfonyl acetamides as NLRP3 inhibitors

Life of this patent

Sulfonyl acetamides as NLRP3 inhibitors

Life of this patent

Abstract

Claims20